[Treatment of heart failure and preserved systolic function].
Dahlström
Ulf
U
Institutionen för medicin och vård, Linköpings universitet. ulf.dahlstrom@lio.se
Boman
Kurt
K
Brodin
Lars-Ake
LA
Hagerman
Inger
I
Willenheimer
Ronnie
R
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003971:Diastole / Q000187:drug effects / Q000502:physiology; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D013599:Systole / Q000187:drug effects / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D004232:Diuretics